Development of replication-deficient adenovirus malaria vaccines

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01BWith Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP

(2016) Tommy Rampling et al.   JOURNAL OF INFECTIOUS DISEASES

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial

(2016) Milagritos D Tapia et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study

(2016) Olga De Santis et al.   LANCET INFECTIOUS DISEASES

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants

(2016) Muhammed O Afolabi et al.   MOLECULAR THERAPY

Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

(2016) Andrew S Ishizuka et al.   NATURE MEDICINE

Status of vaccine research and development of vaccines for malaria

(2016) Ashley J. Birkett   VACCINE

Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses

(2016) Christine S. Rollier et al.   VACCINE

A Model to Study the Impact of Polymorphism Driven Liver-Stage Immune Evasion by Malaria Parasites, to Help Design Effective Cross-Reactive Vaccines

(2016) Kirsty L. Wilson et al.   Frontiers in Microbiology

Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever

(2016) George M. Warimwe et al.   Scientific Reports

Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology

(2016) Yuanyuan Li et al.   Scientific Reports

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

(2015)   LANCET

Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults

(2015) Christian F. Ockenhouse et al.   PLoS One

Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults

(2015) Caroline Ogwang et al.   Science Translational Medicine

From the draining lymph node to the liver: the induction and effector mechanisms of malaria-specific CD8+ T cells

(2015) Andrea J. Radtke et al.   Seminars in Immunopathology

Cross-stage immunity for malaria vaccine development

(2015) Wiebke Nahrendorf et al.   VACCINE

A malaria vaccine for travelers and military personnel: Requirements and top candidates

(2015) Nimfa Teneza-Mora et al.   VACCINE

Induction of CD8+ T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine

(2015) Frances E. Pearson et al.   VACCINE

Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines

(2015) Thomas L. Richie et al.   VACCINE

Progress with viral vectored malaria vaccines: A multi-stage approach involving “unnatural immunity”

(2015) Katie J. Ewer et al.   VACCINE

Controlled Human Malaria Infection (CHMI) differentially affects cell-mediated and antibody responses to CSP and AMA1 induced by adenovirus vaccines with and without DNA-priming

(2015) Martha Sedegah et al.   Human Vaccines & Immunotherapeutics

Lymph-Node Resident CD8α+ Dendritic Cells Capture Antigens from Migratory Malaria Sporozoites and Induce CD8+ T Cell Responses

(2015) Andrea J. Radtke et al.   PLoS Pathogens

Plasmodium cellular effector mechanisms and the hepatic microenvironment

(2015) Ute Frevert et al.   Frontiers in Microbiology

Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax

(2015) Simone C. de Cassan et al.   Frontiers in Immunology

Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PfUIS3, PfLSA1 and PfLSAP2 in Multiple Strains of Mice

(2015) Rhea J. Longley et al.   PLoS One

Comparative Assessment of Transmission-Blocking Vaccine Candidates against Plasmodium falciparum

(2015) M. C. Kapulu et al.   Scientific Reports

Controlled Human Malaria Infection of Tanzanians by Intradermal Injection of Aseptic, Purified, Cryopreserved Plasmodium falciparum Sporozoites

(2014) Seif Shekalaghe et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Malaria Immunity in Man and Mosquito: Insights into Unsolved Mysteries of a Deadly Infectious Disease

(2014) Peter D. Crompton et al.   Annual Review of Immunology

Independent Emergence of Artemisinin Resistance Mutations Among Plasmodium falciparum in Southeast Asia

(2014) Shannon Takala-Harrison et al.   JOURNAL OF INFECTIOUS DISEASES

Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals

(2014) Susanne H. Hodgson et al.   JOURNAL OF INFECTIOUS DISEASES

Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial

(2014) Susanne H Hodgson et al.   MOLECULAR THERAPY

Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations

(2014) Domtila Kimani et al.   MOLECULAR THERAPY

Sterile Immunity to Malaria after DNA Prime/Adenovirus Boost Immunization Is Associated with Effector Memory CD8+T Cells Targeting AMA1 Class I Epitopes

(2014) Martha Sedegah et al.   PLoS One

Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure

(2014) Sumi Biswas et al.   PLoS One

A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS

(2014) Eoghan de Barra et al.   PLoS One

Immune Activation with HIV Vaccines

(2014) A. S. Fauci et al.   SCIENCE

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory

(2014) L. Swadling et al.   Science Translational Medicine

Tissue signatures influence the activation of intrahepatic CD8+ T cells against malaria sporozoites

(2014) Alexandre Morrot et al.   Frontiers in Microbiology

Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection

(2014) Susanne H. Hodgson et al.   Frontiers in Microbiology

Strategies for Designing and Monitoring Malaria Vaccines Targeting Diverse Antigens

(2014) Alyssa E. Barry et al.   Frontiers in Immunology

Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials

(2013) Stefania Capone et al.   Expert Review of Vaccines

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection

(2013) Sean C. Elias et al.   IMMUNOLOGY

The Survival of Memory CD8 T Cells That Is Mediated by IL-15 Correlates with Sustained Protection Against Malaria

(2013) S. Zarling et al.   JOURNAL OF IMMUNOLOGY

Assessment of Immune Interference, Antagonism, and Diversion following Human Immunization with Biallelic Blood-Stage Malaria Viral-Vectored Vaccines and Controlled Malaria Infection

(2013) S. C. Elias et al.   JOURNAL OF IMMUNOLOGY

Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization

(2013) K. M. Quinn et al.   JOURNAL OF IMMUNOLOGY

Malaria vaccine technology roadmap

(2013) Vasee S Moorthy et al.   LANCET

Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens

(2013) Richard D Antrobus et al.   MOLECULAR THERAPY

A molecular marker of artemisinin-resistant Plasmodium falciparum malaria

(2013) Frédéric Ariey et al.   NATURE

Imaging mosquito transmission of Plasmodium sporozoites into the mammalian host: Immunological implications

(2013) Jerome P. Vanderberg   PARASITOLOGY INTERNATIONAL

Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults

(2013) Caroline Ogwang et al.   PLoS One

DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity

(2013) Ilin Chuang et al.   PLoS One

Dry-Coated Live Viral Vector Vaccines Delivered by Nanopatch Microprojections Retain Long-Term Thermostability and Induce Transgene-Specific T Cell Responses in Mice

(2013) Frances E. Pearson et al.   PLoS One

A Phase 1b Randomized, Controlled, Double-Blinded Dosage-Escalation Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkinabe Healthy Adults 18 to 45 Years of Age

(2013) Alphonse Ouédraogo et al.   PLoS One

Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine

(2013) R. A. Seder et al.   SCIENCE

Adenoviruses isolated from wild gorillas are closely related to human species C viruses

(2013) McVey Duncan et al.   VIROLOGY

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation

(2013) Katie J. Ewer et al.   Nature Communications

Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults

(2013) C Buddy Creech et al.   Human Vaccines & Immunotherapeutics

Human adenovirus 5-vectoredPlasmodium falciparumNMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection

(2013) Cindy Tamminga et al.   Human Vaccines & Immunotherapeutics

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)

(2012) Lindsey R. Baden et al.   JOURNAL OF INFECTIOUS DISEASES

Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector

(2012) Geraldine A. O’Hara et al.   JOURNAL OF INFECTIOUS DISEASES

Comparative Analysis of Simian Immunodeficiency Virus Gag-Specific Effector and Memory CD8+T Cells Induced by Different Adenovirus Vectors

(2012) Wendy G. Tan et al.   JOURNAL OF VIROLOGY

Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity

(2012) Arturo Reyes-Sandoval et al.   MOLECULAR THERAPY

ChAd63-MVA–vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans

(2012) Susanne H Sheehy et al.   MOLECULAR THERAPY

Fusion of the Mycobacterium tuberculosis Antigen 85A to an Oligomerization Domain Enhances Its Immunogenicity in Both Mice and Non-Human Primates

(2012) Alexandra J. Spencer et al.   PLoS One

Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors

(2012) Susanne H. Sheehy et al.   PLoS One

Protective CD8+ T lymphocytes in Primates Immunized with Malaria Sporozoites

(2012) Walter R. Weiss et al.   PLoS One

Long Term Protection after Immunization with P. berghei Sporozoites Correlates with Sustained IFNγ Responses of Hepatic CD8+ Memory T Cells

(2012) Krystelle Nganou-Makamdop et al.   PLoS One

Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-Existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses

(2012) Joseph T. Bruder et al.   PLoS One

Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection

(2012) Gareth Betts et al.   PLoS One

Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species

(2012) S. Colloca et al.   Science Translational Medicine

Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stagePlasmodium falciparumDNA vaccine combined with escalating dose human GM-CSF DNA

(2012) Thomas L. Richie et al.   Human Vaccines & Immunotherapeutics

Memory CD8 T Cells Specific for Plasmodia Liver-Stage Antigens Maintain Protracted Protection Against Malaria

(2012) Urszula Krzych et al.   Frontiers in Immunology

T-cell-inducing vaccines - what’s the future

(2011) Sarah C. Gilbert   IMMUNOLOGY

Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine

(2011) Nicole Frahm et al.   JOURNAL OF CLINICAL INVESTIGATION

CD8+ T Effector Memory Cells Protect against Liver-Stage Malaria

(2011) A. Reyes-Sandoval et al.   JOURNAL OF IMMUNOLOGY

HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable

(2011) S. C. De Rosa et al.   JOURNAL OF IMMUNOLOGY

Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors

(2011) Susanne H Sheehy et al.   MOLECULAR THERAPY

Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two Alleles of Plasmodium falciparum AMA1

(2011) Sumi Biswas et al.   PLoS One

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)

(2011) Gavin J. Churchyard et al.   PLoS One

Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults

(2011) Martha Sedegah et al.   PLoS One

Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity

(2011) J. E. Epstein et al.   SCIENCE

The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody

(2011) Alexander D. Douglas et al.   Nature Communications

The Th1 Immune Response to Plasmodium falciparum Circumsporozoite Protein Is Boosted by Adenovirus Vectors 35 and 26 with a Homologous Insert

(2010) K. Radosevic et al.   Clinical and Vaccine Immunology

Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses

(2010) Richard A. Koup et al.   PLoS One

Sterile Protection against Plasmodium knowlesi in Rhesus Monkeys from a Malaria Vaccine: Comparison of Heterologous Prime Boost Strategies

(2009) George Jiang et al.   PLoS One

Apical membrane antigen 1: a malaria vaccine candidate in review

(2008) Edmond J. Remarque et al.   TRENDS IN PARASITOLOGY